NCT02913508View on ClinicalTrials.gov

Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Ulcerative ColitisCrohn's Disease

Interventions

DRUG

Vedolizumab intravenous injection

Vedolizumab intravenous injection

DRUG

Vedolizumab subcutaneous injection

Vedolizumab subcutaneous injection

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY

NCT02913508 - Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease | Biotech Hunter | Biotech Hunter